DOCSLIB.ORG

Reports on Individual Drugs

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Reports on Individual Drugs WHO Drug Information Vol. 10, No.1, 1996 Reports on Individual Drugs Lamivudine: impressive benefits in emergence of highly resistant mutant virus (18). In vitro selection experiments have shown that a 500- combination with zidovudine fold increase in resistance to lamivudine is conferred by a mutation at a single site (codon 184) The value of zidovudine and other first generation of the HIV-1 reverse transcriptase gene (19-21 ). antiretroviral nucleoside analogues has been seriously compromised by rapid emergence of The clinical value of lamivudine in combination resistant variants of HIV (1-5). In some cases, therapy arises because, not only do virions clinically-evident drug resistance has developed resistant to lamivudine remain sensitive to within a matter of weeks. Several clinical studies zidovudine in vitro (21, 22), but introduction of this have suggested that the clinical response might be mutation resensitizes virions previously resistant to prolonged by using these analogues in com­ zidovudine (21 ), and mutations conferring bination. Gains obtained with combinations of resistance to zidovudine appear more slowly in zidovudine and didanosine (6-8) were initially patients who are also receiving lamivudine (23). reported to be modest. However, a preliminary Moreover, both drugs act synergistically against report of results obtained in a European/Australian primary clinical isolates in vitro (24); they may multicentre study indicates that, after some two target different populations of infected cells (25); years of use, zidovudine administered in and lamivudine is well tolerated in comparison with combination with either didanosine or zalcitabine, other nucleoside analogues (26). confers "substantial and significant advantage in survival and disease-free survival" over zidovudine The recently reported clinical study (1 0), which was monotherapy (9). Meanwhile, impressive early conducted at 26 hospital centres in North America, results have recently been reported with a com­ was a double-blind, randomized, placebo-controlled bination of zidovudine and lamivudine among trial lasting 24 weeks, with a blinded extension patients in the early stages of HIV infection (1 0). phase lasting an additional 28 weeks. Patients The nucleoside analogues act by inhibiting HIV-1 received one of four regimens: lamivudine, 300 mg reverse transcriptase after phosphorylation in vivo every 12 hours; zidovudine, 200 mg every 8 hours; (11 ). This viral enzyme is crucial to the replication or zidovudine 200 mg every 12 hours in combina­ of HIV since it transmutes the single-stranded RNA tion, respectively, with lamivudine 150 mg or genome of HIV-1 into double-stranded DNA which lamivudine 300 mg. integrates into the chromosomal apparatus of the cell. This inserted DNA (or provirus) generates new Despite the expectation that lamivudine resistance retroviral RNA through the normal mechanisms of would rapidly emerge, there was no significant cellular transcription. The gene that expresses the difference in time-related changes in plasma levels reverse transcriptase enzyme is subject to a high of CD4 cells or of HIV-1 RNA between the two frequency of mutations (12, 13) and, in the groups receiving monotherapy. Adding lamivudine presence of zidovudine, mutants that confer to zidovudine strongly potentiated immunological resistance to the drug are preferentially selected. and antiviral activity, as measured by these two Typically, resistance to zidovudine develops indicators, without altering the safety profile progressively, since it results from the accumulation associated with zidovudine. After one year, patients of several independent mutations (14). remained significantly more responsive to the combination regimens: In vitro, lamivudine has activity against a wide range of isolates of HIV-1 including variants • the mean CD4 cell count had fallen among patients receiving zidovudine monotherapy by resistant to zidovudine (15-17). However, when 3 given as monotherapy to patients with early HIV-1 -53±14 cells/mm , whereas among patients infection, a marked decline in viral load (serum receiving each of the combination therapies, the count had risen by a mean of approximately HIV-1 RNA) is consistently followed within a few 3 weeks by a rise that is coincident with the +60±20 cells/mm . 5 Reports on Individual Drugs WHO Drug Information Vol. 10, No.1, 1996 • in a subgroup of 224 patients whose plasma 7. Collier, A., Coombs, R., Fischl, M. et al. Combination initially contained more than 20 000 copies of HIV therapy with zidovudine and didanosine compared with RNNml, the mean reduction was estimated to be zidovudine alone in HIV-1 infection. Annals of Internal some 35% among patients receiving zidovudine Medicine, 119: 786-793 (1993). monotherapy, as opposed to some 99% among 8. Yarchoan, R., Lietzau, J., Nguyen, B. et al. A rand­ those receiving either of the combination omized pilot study of alternating or simultaneous regimens. zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus. Journal of As yet, it is too early to speculate what impact this Infectious Diseases, 169:9-17 (1994). [Erratum: ibid, potentiation will have on mortality or symptom-free 170:260 (1994)] survival. Such interaction may not be unique since 9. Gazzard, B. on behalf of the International Coordinating both didanosine and zalcitabine have recently been Committee. Further results from the European/Australian reported to inhibit emergence of one of the Delta trial. Abstracts of the Third Conference on mutations that confers resistance to zidovudine Retroviruses and Opportunistic Infections. Washington, (27). Moreover, no mutations associated with DC, 1996, p. 161. didanosine or zalcitabine were detected in patients 10. Eron, J., Benoit, S., Jemsek, J. et al. Treatment with who had received these drugs in combination with lamivudine, zidovudine, or both in HIV-positive patients zidovudine for some two years (27). Further with 200 to 500 CD4+ cells per cubic millimeter. New prospective studies are needed that will examine England Journal of Medicine, 333: 1662-1669 (1995). clinical endpoints. At this stage, these results are highly impressive. Given recent success in the 11. Furman, P., Fyfe, J., StClair, M. et al. Phosphorylation development of potent non-nucleoside antiretroviral of 3'-azido-3'-deoxythymidine and selective interaction of compounds (28), the prospect of tangible achieve­ the 5'-triphosphate with human immunodeficiency virus ment in the management of HIV infection through reverse transcriptase. Proceedings of the National combination therapy has been suddenly and Academy of Sciences, USA, 83: 8333-8337 (1986). dramatically advanced. 12. Japour, A., Welles, S., d'Aquila, R. et al. Prevalence and clinical significance of zidovudine resistance References mutations in human immunodeficiency virus isolated from 1. Larder, B., Darby, G., Richmann, D. HIV with reduced patients after long-term zidovudine treatment. Journal of sensitivity to zidovudine (AZT) isolated during prolonged Infectious Diseases, 171: 1172-1179 (1995). therapy. Science, 243: 1731-1734 (1989). 13. Loveday, C., Kaye, S., Tenant-Flowers M. et al. HIV-1 2. Rooke, R., Tremblay, M., Soudeyns, H. et al. Isolation RNA serum-load and resistant viral genotypes during of drug-resistant variants of HIV-1 from patients on long­ early zidovudine therapy. Lancet, 345: 82Q-824 (1995). term zidovudine therapy. AIDS, 3: 411-415 (1989). 14. Larder, B., Kemp, S. Multiple mutations in HIV-1 3. Richman, D., Grimes, J., Lagakos, S. Effect of stage of reverse transcriptase confer high-level resistance to disease and drug dose on zidovudine susceptibilities of zidovudine (AZT). Science, 246: 1155-1158 (1989). isolates of human immunodeficiency virus. Journal of the Acquired Immune Deficiency Syndrome, 3: 743-746 15. Schinazi, R., Chu, C., Peck, A. Activities of the four (1990). optical isomers of 2', 3'-dideoxy-3'-thiacytidine (BCH-189) against human immunodeficiency virus type 1 in human 4. Kozal, M., Shafer, R., Winters, M. et al. A mutation in lymphocytes. Antimicrobial Agents and Chemotherapy, human immunodeficiency virus reverse transcriptase and 37: 875-881 (1993). decline in CD4 lymphocyte numbers in long-term zido­ vudine recipients. Journal of Infectious Diseases, 167: 16. Coates, J., Cammack, N., Jenkinson, H. et al. (-)-2'­ 526-532 (1993). deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and 2 replication 5. loannidis, J., Cappelleri, J., Lau, J. et al. Early or in vivo. Antimicrobial Agents and Chemotherapy, 36: deferred zidovudine therapy in HIV-infected patients with­ 733-739(1992). out an AIDS-defining illness. Annals of Internal Medicine, 122: 856-866 (1995). 17. Coates, J., Cammack, N., Jenkinson, H. et al. The separated enantiomers of 2'-deoxy-3'-thiacytidine (BCH 6. Caliendo, A., Hirsch, M. Combination therapy for infec­ 189) both inhibit human immunodeficiency virus replica­ tion due to human immunodeficiency virus type 1. Clinical tion in vitro. Antimicrobial Agents and Chemotherapy, 36: Infectious Diseases,18: 516-524 (1994). [Erratum: ibid, 2025 (1992). 19: 379 (1994)]. 6 WHO Drug Information Vol. 10, No.1, 1996 Reports on Individual Drugs 18. Schuurman, R., Nijhuis, M., van Leeuwen, R. et al. Lamivudine: encouraging Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus experience in chronic populations in persons treated with lamivudine (3TC). Journal oflnfectious
Load more

Recommended publications
  • Novel Therapeutics for Epstein–Barr Virus
    molecules Review Novel Therapeutics for Epstein–Barr Virus Graciela Andrei *, Erika Trompet and Robert Snoeck Laboratory of Virology and Chemotherapy, Department of Microbiology and Immunology, Rega Institute for Medical Research, KU Leuven, 3000 Leuven, Belgium; [email protected] (E.T.); [email protected] (R.S.) * Correspondence: [email protected]; Tel.: +32-16-321-915 Academic Editor: Stefano Aquaro Received: 15 February 2019; Accepted: 4 March 2019; Published: 12 March 2019 Abstract: Epstein–Barr virus (EBV) is a human γ-herpesvirus that infects up to 95% of the adult population. Primary EBV infection usually occurs during childhood and is generally asymptomatic, though the virus can cause infectious mononucleosis in 35–50% of the cases when infection occurs later in life. EBV infects mainly B-cells and epithelial cells, establishing latency in resting memory B-cells and possibly also in epithelial cells. EBV is recognized as an oncogenic virus but in immunocompetent hosts, EBV reactivation is controlled by the immune response preventing transformation in vivo. Under immunosuppression, regardless of the cause, the immune system can lose control of EBV replication, which may result in the appearance of neoplasms. The primary malignancies related to EBV are B-cell lymphomas and nasopharyngeal carcinoma, which reflects the primary cell targets of viral infection in vivo. Although a number of antivirals were proven to inhibit EBV replication in vitro, they had limited success in the clinic and to date no antiviral drug has been approved for the treatment of EBV infections. We review here the antiviral drugs that have been evaluated in the clinic to treat EBV infections and discuss novel molecules with anti-EBV activity under investigation as well as new strategies to treat EBV-related diseases.
    [Show full text]
  • Synthesis of Ribavirin, Tecadenoson, and Cladribine by Enzymatic Transglycosylation
    catalysts Article Synthesis of Ribavirin, Tecadenoson, and Cladribine by Enzymatic Transglycosylation 1, 2 2,3 2 Marco Rabuffetti y, Teodora Bavaro , Riccardo Semproli , Giulia Cattaneo , Michela Massone 1, Carlo F. Morelli 1 , Giovanna Speranza 1,* and Daniela Ubiali 2,* 1 Department of Chemistry, University of Milan, via Golgi 19, I-20133 Milano, Italy; marco.rabuff[email protected] (M.R.); [email protected] (M.M.); [email protected] (C.F.M.) 2 Department of Drug Sciences, University of Pavia, viale Taramelli 12, I-27100 Pavia, Italy; [email protected] (T.B.); [email protected] (R.S.); [email protected] (G.C.) 3 Consorzio Italbiotec, via Fantoli 15/16, c/o Polo Multimedica, I-20138 Milano, Italy * Correspondence: [email protected] (G.S.); [email protected] (D.U.); Tel.: +39-02-50314097 (G.S.); +39-0382-987889 (D.U.) Present address: Department of Food, Environmental and Nutritional Sciences, University of Milan, y via Mangiagalli 25, I-20133 Milano, Italy. Received: 7 March 2019; Accepted: 8 April 2019; Published: 12 April 2019 Abstract: Despite the impressive progress in nucleoside chemistry to date, the synthesis of nucleoside analogues is still a challenge. Chemoenzymatic synthesis has been proven to overcome most of the constraints of conventional nucleoside chemistry. A purine nucleoside phosphorylase from Aeromonas hydrophila (AhPNP) has been used herein to catalyze the synthesis of Ribavirin, Tecadenoson, and Cladribine, by a “one-pot, one-enzyme” transglycosylation, which is the transfer of the carbohydrate moiety from a nucleoside donor to a heterocyclic base. As the sugar donor, 7-methylguanosine iodide and its 20-deoxy counterpart were synthesized and incubated either with the “purine-like” base or the modified purine of the three selected APIs.
    [Show full text]
  • A Cell-Based Reporter Assay for Screening Inhibitors of MERS Coronavirus RNA-Dependent RNA Polymerase Activity
    Journal of Clinical Medicine Article A Cell-Based Reporter Assay for Screening Inhibitors of MERS Coronavirus RNA-Dependent RNA Polymerase Activity Jung Sun Min 1,2, Geon-Woo Kim 1,2, Sunoh Kwon 1,2,* and Young-Hee Jin 2,3,* 1 Herbal Medicine Research Division, Korea Institute of Oriental Medicine, Daejeon 34054, Korea; [email protected] (J.S.M.); [email protected] (G.-W.K.) 2 Center for Convergent Research of Emerging Virus Infection, Korea Research Institute of Chemical Technology, Daejeon 34114, Korea 3 KM Application Center, Korea Institute of Oriental Medicine, Daegu 41062, Korea * Correspondence: [email protected] (S.K.); [email protected] (Y.-H.J.); Tel.: +82-42-868-9675 (S.K.); +82-42-610-8850 (Y.-H.J.) Received: 25 June 2020; Accepted: 20 July 2020; Published: 27 July 2020 Abstract: Severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and coronavirus disease 2019 (COVID-19) are emerging zoonotic diseases caused by coronavirus (CoV) infections. The viral RNA-dependent RNA polymerase (RdRp) has been suggested as a valuable target for antiviral therapeutics because the sequence homology of CoV RdRp is highly conserved. We established a cell-based reporter assay for MERS-CoV RdRp activity to test viral polymerase inhibitors. The cell-based reporter system was composed of the bicistronic reporter construct and the MERS-CoV nsp12 plasmid construct. Among the tested nine viral polymerase inhibitors, ribavirin, sofosbuvir, favipiravir, lamivudine, zidovudine, valacyclovir, vidarabine, dasabuvir, and remdesivir, only remdesivir exhibited a dose-dependent inhibition. Meanwhile, the Z-factor and Z0-factor of this assay for screening inhibitors of MERS-CoV RdRp activity were 0.778 and 0.782, respectively.
    [Show full text]
  • Vidarabine Phosphate (BANM, USAN, Rinnm) Stability
    912 Antivirals Pharmacopoeias. In US. ◊ Reviews. Pharmacopoeias. In US. USP 31 (Valganciclovir Hydrochloride). A white to off-white 1. Freeman RB. Valganciclovir: oral prevention and treatment of USP 31 (Vidarabine). A white to off-white powder. Very slightly powder. Freely soluble in alcohol; practically insoluble in ace- cytomegalovirus in the immunocompromised host. Expert Opin soluble in water; slightly soluble in dimethylformamide. Store in tone or in ethyl acetate; slightly soluble in hexane; very soluble Pharmacother 2004; 5: 2007–16. airtight containers. in isopropyl alcohol. Store in airtight containers at a temperature 2. Cvetković RS, Wellington K. Valganciclovir: a review of its use in the management of CMV infection and disease in immuno- of 25°, excursions permitted between 15° and 30°. compromised patients. Drugs 2005; 65: 859–78. Vidarabine Phosphate (BANM, USAN, rINNM) Stability. References. Administration in renal impairment. Doses of oral valgan- Ara-AMP; Arabinosyladenine Monophosphate; CI-808; Fosfato 1. Anaizi NH, et al. Stability of valganciclovir in an extemporane- ciclovir should be reduced in renal impairment according to cre- de vidarabina; Vidarabine 5′-Monophosphate; Vidarabine, Phos- ously compounded oral liquid. Am J Health-Syst Pharm 2002; atinine clearance (CC). Licensed product information recom- phate de; Vidarabini Phosphas. 9-β-D-Arabinofuranosyladenine 59: 1267–70. mends the following doses: 5′-(dihydrogen phosphate). 2. Henkin CC, et al. Stability of valganciclovir in extemporaneous- • CC 40 to 59 mL/minute: 450 mg twice daily for induction and Видарабина Фосфат ly compounded liquid formulations. Am J Health-Syst Pharm 2003; 60: 687–90. 450 mg daily for maintenance or prevention C10H14N5O7P = 347.2.
    [Show full text]
  • Clinical Response to Glycyrrhizinic Acid in Genital Infection Due to Human
    Clinics and Practice 2011; volume 1:e93 Clinical response to and only one patient progressed to cervical intraepithelial neoplasia (CIN) II. The use of Correspondence: Marcelino Hernández Valencia, glycyrrhizinic acid in genital GA proved to be effective in resolving clinical Hospital General de Ecatepec Dr. José Ma. infection due to human HPV lesions. For cervical lesions with epithe - Rodríguez, ISEM y Unidad de Investigación en papillomavirus and low-grade lial changes (LSIL), treatment may be Enfermedades Endocrinas, Hospital de required for a longer period as with other Especialidades, CMN Siglo XXI, IMSS, México, squamous intraepithelial lesion D.F., Mexico. drugs used for this infection, as well as mon - E-mail: [email protected] itoring for at least 1 year according to the nat - Marcelino Hernández Valencia, ural evolution of the disease. Key words: human papilloma virus, low-grade Adia Carrillo Pacheco, squamous intraepithelial lesion, glycyrrhizinic Tomás Hernández Quijano, acid. Antonio Vargas Girón, Carlos Vargas López Introduction Received for publication: 29 September 2011. Accepted for publication: 10 October 2011. Hospital General de Ecatepec Dr. José Ma. Rodríguez, ISEM y Unidad de In recent years, human papilloma virus This work is licensed under a Creative Commons Investigación en Enfermedades (HPV) has become one of the most frequent Attribution NonCommercial 3.0 License (CC BY- Endocrinas, Hospital de Especialidades, sexually transmitted infections, producing NC 3.0). initial lesions known as genital warts. These CMN Siglo XXI, IMSS, México, D.F., may appear as small individual pimples or as ©Copyright M. Hernández Valencia et al., 2011 Mexico small, flat or raised groups and can appear Licensee PAGEPress, Italy 1,2 Clinics and Practice 2011; 1:e93 weeks or months after sexual intercourse.
    [Show full text]
  • Current Drugs to Treat Infections with Herpes Simplex Viruses-1 and -2
    viruses Review Current Drugs to Treat Infections with Herpes Simplex Viruses-1 and -2 Lauren A. Sadowski 1,†, Rista Upadhyay 1,2,†, Zachary W. Greeley 1,‡ and Barry J. Margulies 1,3,* 1 Towson University Herpes Virus Lab, Department of Biological Sciences, Towson University, Towson, MD 21252, USA; [email protected] (L.A.S.); [email protected] (R.U.); [email protected] (Z.W.G.) 2 Towson University Department of Chemistry, Towson, MD 21252, USA 3 Molecular Biology, Biochemistry, and Bioinformatics Program, Towson University, Towson, MD 21252, USA * Correspondence: [email protected] † Authors contributed equally to this manuscript. ‡ Current address: Becton-Dickinson, Sparks, MD 21152, USA. Abstract: Herpes simplex viruses-1 and -2 (HSV-1 and -2) are two of the three human alphaher- pesviruses that cause infections worldwide. Since both viruses can be acquired in the absence of visible signs and symptoms, yet still result in lifelong infection, it is imperative that we provide interventions to keep them at bay, especially in immunocompromised patients. While numerous experimental vaccines are under consideration, current intervention consists solely of antiviral chemotherapeutic agents. This review explores all of the clinically approved drugs used to prevent the worst sequelae of recurrent outbreaks by these viruses. Keywords: acyclovir; ganciclovir; cidofovir; vidarabine; foscarnet; amenamevir; docosanol; nelfi- navir; HSV-1; HSV-2 Citation: Sadowski, L.A.; Upadhyay, R.; Greeley, Z.W.; Margulies, B.J. Current Drugs to Treat Infections 1. Introduction with Herpes Simplex Viruses-1 and -2. The world of anti-herpes simplex (anti-HSV) agents took flight in 1962 with the FDA Viruses 2021, 13, 1228.
    [Show full text]
  • Usage of Antivirals and the Occurrence of Antiviral Resistance in Norway 2018
    REPORT 2019 Usage of Antivirals and the Occurrence of Antiviral Resistance in Norway 2018 RAVN Resistensovervåking av virus i Norge Resistance against Antivirals in Norway Usage of Antivirals and the Occurrence of Antiviral resistance in Norway 2018 RAVN Resistensovervåkning av virus i Norge Resistance against antivirals in Norway 2 Published by the Norwegian Institute of Public Health Division of Infection Control and Environmental Health Department for Infectious Disease registries October 2019 Title: Usage of Antivirals and the Occurrence of Antiviral Resistance in Norway 2018. RAVN Ordering: The report can be downloaded as a pdf at www.fhi.no Graphic design cover: Fete Typer ISBN nr: 978-82-8406-032-3 Emneord (MeSH): Antiviral resistance Any usage of data from this report should include a specific reference to RAVN. Suggested citation: RAVN. Usage of Antivirals and the Occurrence of Antiviral Resistance in Norway 2018. Norwegian Institute of Public Health, Oslo 2019 Resistance against antivirals in Norway • Norwegian Institute of Public Health 3 Table of contents Introduction _________________________________________________________________________ 4 Contributors and participants __________________________________________________________ 5 Sammendrag ________________________________________________________________________ 6 Summary ___________________________________________________________________________ 8 1 Antivirals and development of drug resistance ______________________________________ 10 2 The usage of antivirals in Norway
    [Show full text]
  • A Computational Approach to Aid Clinicians in Selecting Anti-Viral
    www.nature.com/scientificreports OPEN A computational approach to aid clinicians in selecting anti‑viral drugs for COVID‑19 trials Aanchal Mongia1, Sanjay Kr. Saha2, Emilie Chouzenoux3* & Angshul Majumdar1* The year 2020 witnessed a heavy death toll due to COVID‑19, calling for a global emergency. The continuous ongoing research and clinical trials paved the way for vaccines. But, the vaccine efcacy in the long run is still questionable due to the mutating coronavirus, which makes drug re‑positioning a reasonable alternative. COVID‑19 has hence fast‑paced drug re‑positioning for the treatment of COVID‑19 and its symptoms. This work builds computational models using matrix completion techniques to predict drug‑virus association for drug re‑positioning. The aim is to assist clinicians with a tool for selecting prospective antiviral treatments. Since the virus is known to mutate fast, the tool is likely to help clinicians in selecting the right set of antivirals for the mutated isolate. The main contribution of this work is a manually curated database publicly shared, comprising of existing associations between viruses and their corresponding antivirals. The database gathers similarity information using the chemical structure of drugs and the genomic structure of viruses. Along with this database, we make available a set of state‑of‑the‑art computational drug re‑positioning tools based on matrix completion. The tools are frst analysed on a standard set of experimental protocols for drug target interactions. The best performing ones are applied for the task of re‑positioning antivirals for COVID‑19. These tools select six drugs out of which four are currently under various stages of trial, namely Remdesivir (as a cure), Ribavarin (in combination with others for cure), Umifenovir (as a prophylactic and cure) and Sofosbuvir (as a cure).
    [Show full text]
  • Common Study Protocol for Observational Database Studies WP5 – Analytic Database Studies
    Arrhythmogenic potential of drugs FP7-HEALTH-241679 http://www.aritmo-project.org/ Common Study Protocol for Observational Database Studies WP5 – Analytic Database Studies V 1.3 Draft Lead beneficiary: EMC Date: 03/01/2010 Nature: Report Dissemination level: D5.2 Report on Common Study Protocol for Observational Database Studies WP5: Conduct of Additional Observational Security: Studies. Author(s): Gianluca Trifiro’ (EMC), Giampiero Version: v1.1– 2/85 Mazzaglia (F-SIMG) Draft TABLE OF CONTENTS DOCUMENT INFOOMATION AND HISTORY ...........................................................................4 DEFINITIONS .................................................... ERRORE. IL SEGNALIBRO NON È DEFINITO. ABBREVIATIONS ......................................................................................................................6 1. BACKGROUND .................................................................................................................7 2. STUDY OBJECTIVES................................ ERRORE. IL SEGNALIBRO NON È DEFINITO. 3. METHODS ..........................................................................................................................8 3.1.STUDY DESIGN ....................................................................................................................8 3.2.DATA SOURCES ..................................................................................................................9 3.2.1. IPCI Database .....................................................................................................9
    [Show full text]
  • The Structural Basis for Cancer Drug Interactions with the Catalytic and Allosteric Sites of SAMHD1
    The structural basis for cancer drug interactions with the catalytic and allosteric sites of SAMHD1 Kirsten M. Knechta,1, Olga Buzovetskya,1, Constanze Schneiderb, Dominique Thomasc,d, Vishok Srikantha, Lars Kaderalie, Florentina Tofoleanuf,g, Krystle Reissf, Nerea Ferreirósc,d, Gerd Geisslingerc,d,h, Victor S. Batistaf, Xiaoyun Jii, Jindrich Cinatl Jr.b, Oliver T. Kepplerj, and Yong Xionga,2 aDepartment of Molecular Biophysics and Biochemistry, Yale University, New Haven, CT 06520; bInstitute of Medical Virology, University Hospital Frankfurt, 60596 Frankfurt, Germany; cInstitute of Clinical Pharmacology, Pharmazentrum Frankfurt, Goethe University of Frankfurt, 60590 Frankfurt, Germany; dZentrum für Arzneimittelforschung, -entwicklung, und -sicherheit, Goethe University of Frankfurt, 60590 Frankfurt, Germany; eInstitute of Bioinformatics, University Medicine Greifswald, 17475 Greifswald, Germany; fDepartment of Chemistry, Yale University, New Haven, CT 06520; gNational Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892; hProject Group Translational Medicine and Pharmacology, Frauenhofer Institute for Molecular Biology and Applied Ecology, 60590 Frankfurt, Germany; iThe State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, 210023 Jiangsu, China; and jMax von Pettenkofer-Institute, Department of Virology, Ludwig Maximilians University, 80336 Munich, Germany Edited by Celia A. Schiffer, University of Massachusetts Medical School, Worcester, MA, and accepted by Editorial Board Member Brenda A. Schulman September 6, 2018 (received for review April 2, 2018) SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase canonical dNTPs are both substrates and allosteric activators, and (dNTPase) that depletes cellular dNTPs in noncycling cells to promote this promiscuity allows SAMHD1 to target therapeutic molecules genome stability and to inhibit retroviral and herpes viral replication. that resemble nucleotides in structure.
    [Show full text]
  • The Odyssey of Marine Pharmaceuticals: a Current Pipeline Perspective
    Review The odyssey of marine pharmaceuticals: a current pipeline perspective Alejandro M.S. Mayer1, Keith B. Glaser1,2, Carmen Cuevas3, Robert S. Jacobs4, William Kem5, R. Daniel Little6, J. Michael McIntosh7, David J. Newman8, Barbara C. Potts9 and Dale E. Shuster10 1 Department of Pharmacology, Chicago College of Osteopathic Medicine, Midwestern University, 555 31st Street, Downers Grove, IL 60515, USA 2 Cancer Research, R47J-AP9, Abbott Laboratories, 100 Abbott Park Rd, Abbott Park, IL 60064-6121, USA 3 Research and Development Director, R&D PharmaMar, Avda. de los Reyes, 1 P.I. La Mina Norte, 28770 Colmenar Viejo, Madrid, Spain 4 Ecology, Evolution and Marine Biology, University of California at Santa Barbara, Santa Barbara, CA 93106-9610, USA 5 Department of Pharmacology and Therapeutics, University of Florida College of Medicine, P.O. Box 100267, Gainesville, FL 32610-0267, USA 6 Department of Chemistry and Biochemistry, University of California at Santa Barbara, Santa Barbara, CA 93106-9510, USA 7 Department of Psychiatry, University of Utah, 257 S. 1400 E., Salt Lake City, UT 84112-0840, USA 8 Natural Products Branch, National Cancer Institute, 1003 W. 7th Street, Suite 206, Frederick, MD 21701, USA 9 Nereus Pharmaceuticals, Inc., 10480 Wateridge Circle, San Diego, CA 92121, USA 10 Oncology, Eisai, Inc., 300 Tice Blvd., Woodcliff Lake, NJ 07677, USA The global marine pharmaceutical pipeline consists of vidarabine, Ara-A) were part of the pharmacopeia used to three Food and Drug Administration (FDA) approved treat human disease. It has taken over 30 years for another drugs, one EU registered drug, 13 natural products marine-derived natural product to gain approval and (or derivatives thereof) in different phases of the clinical become part of the pharmacopeia.
    [Show full text]
  • Lamivudine Treatment for Chronic Hepatitis B
    LAMIVUDINE TREATMENT FOR CHRONIC HEPATITIS B P. Honkoop ISBN 90-9011356-8 All rights reserved. No part of this thesis may be reproduced, stored in a retrieval system of any nature, or transmitted in any form by any means, electronic, mechanical, photocopying, recording or otherwise, included a complete or partial transcription, without the prior pennission of the author. W Print: Offse.drui<kerij Ridderprin. B.Y" Ridderkerk LAMIVUDINE TREATMENT FOR CHRONIC HEPATITIS B LAMIVUDINE BEHANDELING VAN CHRONISCHE HEPATITIS B PROEFSCHRIFT ter verkrijging van de graad van doctor aan de Erasmus Universiteit Rotterdam op gezag van de rector magnificus Prof. dr P. W.C. Akkermans M.A. en volgens besluit van het college voor promoties. De openbare verdediging zal plaatsvinden op woensdag 22 april 1998 om llAS uur door Pieter Honkoop geboren te Kampen Promotie commissie Promotor: Prof. dr S.W. Schalm Promotie commissie: Prof. dr W.J. Mooi Prof. dr H.R. Scholte Prof. dr AD.M.E. Osterhaus Co-promotor: Dr R.A. de Man The clinical studies on lamivudine were supported by a grant from Glaxo-\Vellcome. This study was performed at the department of Hepatogastroenterology of the Erasmus University Hospital, Dijkzigt, Rotterdam, The Netherlands. Financial support for this thesis was kindly given by G1axo-Wellcome, Byk, Janssen-Cilag, Schering-Plough, Smith Kline Beecham, MSD, Boehringer Mannheim, Roche, Astra, Yamanouchi and Zambon. "Gee! OilS heden ons dagelijks brood" Mattheus 6: J J Aan Willlla en Pieler jr. Aan mijn moeder Tel' nagedachtenis aan mijn vader
    [Show full text]